metformin vs glp 1 Comparing Glucagon‐like peptide‐1 receptor agonists versus in drug‐naive patients: A nationwide cohort study - Sørensen - 2024 - Journal of Diabetes Too Good to Be True?'

Source: Polypeptide In April 2005, Byetta (the commercial name for Exenatide) was approved by the FDA for clinical use in the treatment of Type 2 diabetes

Among those who no longer took the GLP-1, 82 percent who lost weight regained 25 percent or more of their initial weight loss within a year of stopping the drug

For patients with severe obesity (BMI 35+), surgery remains the gold standard with proven outcomes that no other intervention matches

The primary endpoint was major adverse cardiovascular events (often called MACE), a combined measure of: Cardiovascular death Nonfatal heart attack Nonfatal stroke Over a median follow-up of about 3.5 years, semaglutide reduced the relative risk of these events by about 20% compared with placebo

The concentrations of Exe4 and other hepatic markers in plasma were assessed using commercially available assay kits (Exe4: Abcam, AST and ALT: Sigma-Aldrich, Albumin: Fuji Rebis) following the manufacturers protocols, and the absorbance of each sample was measured using a plate reader

u , Insulin tolerance test on day 8